Abstract
Following the publication of this article the authors noted that data describing precisely where phosphorylation sites in proteins modulated following JAK1 or JAK3 inhibition in mutant T-ALL samples was not clearly annotated. Therefore an additional sheet has been added to Supplementary Table 2.
Cite
CITATION STYLE
Degryse, S., de Bock, C. E., Demeyer, S., Govaerts, I., Bornschein, S., Verbeke, D., … Dun, M. D. (2018, December 1). Correction to: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia (Leukemia, (2018), 32, 3, (788-800), 10.1038/leu.2017.276). Leukemia. Nature Publishing Group. https://doi.org/10.1038/s41375-018-0241-7
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
